Reference SummarySundberg JP, Mol Carcinog 1997 SEP;20(1):19-32

Title

Comparison of chemical carcinogen skin tumor induction efficacy in inbred, mutant, and hybrid strains of mice: Morphologic variations of induced tumors and absence of a papillomavirus cocarcinogen.

Authors

Sundberg JP; Sundberg BA; Beamer WG

Journal

Mol Carcinog

Volume

20

Issue

1

Year

1997

Pages

19-32

Abstract

Chemical carcinogen induction of skin tumors in mice was investigated to determine (i) if tumor induction efficacy was modified by single gene mutations, (ii) if the histologic types of the tumors varied with these mutations, and (iii) if a novel papillomavirus was involved as a cocarcinogen. A two-stage carcinogenesis protocol (7,12-dimethylbenz[a]anthracene followed by 12-O- tetradecanoylphorbol-13-acetate) was used to induce papillomas in 14 inbred, two hybrid, and 15 other genetic stocks of mice with inherited, single-gene mutations causing skin abnormalities. Histopathological, immunohistochemical, and Southern blot analyses were performed to determine tumor type and to detect the presence of papillomaviruses. The histologic types of tumors induced included early follicular papillomas, mixed papillomas, exophytic papillomas, hyperplastic papillomas, fibropapillomas, squamous cell carcinomas, and mast cell tumors. The efficacy of tumor induction was influenced by strain background, as seen by the clustering of mice into high-, intermediate-, and nonresponding groups. Similarly, tumor induction efficacy was affected by specific mutant genes that cause skin abnormalities. No evidence of papillomavirus structural antigens or viral genomic DNA was identified in 547 induced tumors. These observations indicate that numerous modifier genes but not papillomaviruses are involved in cutaneous chemical carcinogenesis. (C) 1997 Wiley-Liss, Inc.

Links

J:43880 – Mouse Genome Informatics
9328433 – National Library of Medicine/PubMed

Models

Strain Model Name Treatment Agent(s) Organ Affected Frequency Model Details
DBA/2J Leukocyte - Myelocyte (Granulocyte) - Basophil - Mast cell tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

observed

RHJ/Le Hrrh-J/+ Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

100

ABJ/Le Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

100

I/LnJ Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

100

HRS/J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

83

BALB/cJ Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

83

DBA/2J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

83

C3H/HeJ Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

67

A/J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

64

BALB/cByJ Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

58

(C57BL/6 x CBA/Ca)F1 Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

50

SJL/J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

45

CBA/J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

45

C57BL/6J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

42

IC/Le Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

0

(C57BL/6 x C3HeB/Fe)F1 Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

0

B6C3FeF1-Zdhhc21dep Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

60

B6C3Fe a/a-soc/J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

86

C57BL/6J-Lystbg-J/J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

75

B6.Cg-N/+ Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

100

B6.Cg-Ve/J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

86

IC/LeJ Lbric Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

22

A/J-lgh/J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

0

WLHR/LeJ Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

0

HRS/J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

78

B6CBACaF1-SfnEr/+ Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

44

RHJ/Le Hrrh-J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

100

ABJ/Le-Scd1ab-J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

100

AKR/J-Foxn1nu-str/J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

0

STOCK Sha Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

observed

CByJ.A-Ttc7fsn/J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

25

CBy.A/J Skin tumor
  • 12-O-tetradecanoylphorbol-13-acetate (TPA)
  • 7,12-dimethylbenz[a]anthracene (DMBA)
Skin

0